Invest in smarter healthcare

Lumos Diagnostics is a publicly-traded company listed on the Australian Securities Exchange (ASX:LDX).

World-Class Team

Point-of-care Products

Revenue-Generating Company

Global Commercial and Distribution Partnerships

Register for Lumos investor news and updates.

By entering your email address you are agreeing to our Privacy Policy.

Lumos Diagnostics Holdings Ltd

Key statistics for LDX

Market price
 $0.155
Market cap
 $-
Volume
 5,193,626
Day low
 $0.153
Day high
 $0.165
Change
 $0.000(0.0)
22/10/2025 9:35 am Lumos Commences FebriDx CLIA Waiver Pediatric Study 300KB (3 pages)
16/10/2025 9:34 am Lumos Agreement with WellStreet Urgent Care for FebriDx 296KB (3 pages)
13/10/2025 10:36 am Addendum to Notice of Annual General Meeting 352KB (6 pages)
24/09/2025 3:31 pm FebriDx UK Data Shows Reduced Antibiotic Use & Cost Savings 522KB (4 pages)
24/09/2025 11:25 am ASX SMIDcaps 2025 Conference Presentation 2188KB (12 pages)
19/09/2025 3:58 pm Notice of Annual General Meeting and Proxy Form 713KB (33 pages)
15/09/2025 3:25 pm Section 708A Cleansing Statement 219KB (2 pages)
15/09/2025 3:23 pm Application for quotation of securities - LDX 20KB (9 pages)
11/09/2025 9:52 am Section 708A Cleansing Statement 219KB (2 pages)
11/09/2025 9:50 am Application for quotation of securities - LDX 17KB (2 pages)
09/09/2025 2:53 pm Lumos Signs Second ANZ FebriDx Distribution Agreement 222KB (2 pages)
01/09/2025 9:28 am Lumos secures follow-on PKU contract with Aptatek 297KB (3 pages)
01/09/2025 9:21 am LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study 301KB (3 pages)
28/08/2025 9:23 am Appendix 4G and Corporate Governance 702KB (28 pages)
28/08/2025 9:01 am FY25 Annual Report 6848 (89 pages)
28/08/2025 9:00 am FY25 Appendix 4E 108KB (2 pages)
26/08/2025 3:25 pm Section 708A Cleansing Statement and Excluded Information 118KB (2 pages)
26/08/2025 3:12 pm Application for quotation of securities - LDX 17KB (8 pages)
26/08/2025 9:07 am FY25 Results - Investor Briefing Invitation 172KB (2 pages)
18/08/2025 8:36 am Lumos Announces FebriDx CLIA Waiver Application Submission 199KB (3 pages)
14/08/2025 10:24 am Lumos Partners with PRO-spectus for FebriDx Market Access 204KB (3 pages)
13/08/2025 9:20 am Waiver of ASX Listing Rule 10.1 Granted 236KB (5 pages)
21/07/2025 8:58 am Q4 FY25 Results Investor Briefing 3303KB (30 pages)
21/07/2025 8:56 am Quarterly Activities/Appendix 4C Cash Flow Report 512KB (13 pages)
17/07/2025 10:12 am Proposed issue of securities - LDX 17KB (5 pages)
17/07/2025 10:00 am Lumos Signs Binding Term Sheet for A$5M Loan Facility 265KB (5 pages)
16/07/2025 10:15 am Investor Briefing Presentation 1811KB (17 pages)
16/07/2025 10:13 am Investor Briefing Invitation 217KB (1 pages)
16/07/2025 10:11 am Lumos Signs Pivotal US FebriDx Agreement 274KB (5 pages)
16/07/2025 10:11 am Reinstatement to Quotation 116KB (1 pages)
15/07/2025 9:09 am Suspension from Quotation 252KB (2 pages)
11/07/2025 3:15 pm Trading Halt 261KB (2 pages)
11/07/2025 2:23 pm Pause in Trading 113KB (1 pages)
02/07/2025 12:09 pm Notification of cessation of securities - LDX 15KB (6 pages)
23/06/2025 9:01 am Lumos Receives Research & Development Tax Rebate 224KB (2 pages)
18/06/2025 9:45 am Lumos Reaches FebriDx CLIA Waiver Study Enrolment Milestone 253KB (4 pages)
17/06/2025 9:02 am FebriDx to Support Antimicrobial Stewardship in GP Trial 261KB (3 pages)
02/06/2025 9:08 am Change of Registered Office and Principal Place of Business 207KB (2 pages)
02/06/2025 9:05 am Lumos Reaches Recruitment Milestone in FebriDx Study 253KB (3 pages)
27/05/2025 8:59 am Lumos Secures Sixth US Medicare Reimbursement for FebriDx 308KB (3 pages)
19/05/2025 9:59 am Lumos Secures Fifth US Medicare Reimbursement for FebriDx 309KB (3 pages)
14/05/2025 9:02 am Lumos Advances FebriDx Sales with iMedical Purchase Order 221KB (2 pages)
09/05/2025 10:32 am Notification regarding unquoted securities - LDX 18KB (8 pages)
06/05/2025 8:45 am Q3 FY25 Investor Briefing 3072KB (25 pages)
29/04/2025 9:00 am Quarterly Activities/Appendix 4C Cash Flow Report 355KB (14 pages)
23/04/2025 10:46 am Lumos Secures Further US Medicare Reimbursement for FebriDx 418KB (3 pages)
17/04/2025 10:17 am Lumos Secures Key US Reimbursement Milestones for FebriDx 398KB (3 pages)
14/04/2025 12:02 pm Notification of cessation of securities - LDX 16KB (6 pages)
02/04/2025 11:26 am Investor Presentation 6946KB (35 pages)
24/03/2025 1:51 pm Investor Information Session Invitation 207KB (2 pages)
03/03/2025 10:58 am 1H FY25 Results Investor Briefing 538KB (9 pages)
03/03/2025 8:43 am Hologic Development Agreement Expanded Scope of Works 250KB (3 pages)
27/02/2025 8:30 am Appendix 4D and Half Year Report 672KB (25 pages)
25/02/2025 12:27 pm 1H FY25 Results Investor Briefing Invitation 207KB (2 pages)
05/02/2025 9:08 am Q2 FY25 Results Investor Briefing Invitation 1166KB (17 pages)
31/01/2025 9:02 am Quarterly Activities/Appendix 4C Cash Flow Report 428KB (13 pages)
13/01/2025 1:57 pm Notification of cessation of securities - LDX 14KB (5 pages)
13/01/2025 9:25 am Lumos Partners with MedPro for Sales of FebriDx in the US 296KB (3 pages)
20/12/2024 1:53 pm Listing Rule 6.22.2 Adjustment to Option Exercise Prices 222KB (2 pages)
20/12/2024 10:17 am Application for quotation of securities - LDX 17KB (8 pages)
20/12/2024 10:16 am Section 708A Cleansing Statement 189KB (2 pages)
19/12/2024 3:53 pm Commencement of FebriDx CLIA Waiver Study 341KB (3 pages)
13/12/2024 2:34 pm Notification regarding unquoted securities - LDX opens new window 19KB (8 pages)
10/12/2024 8:54 am Change of Director's Interest Notice - DW 306KB (3 pages)
06/12/2024 10:05 am Application for quotation of securities - LDX 17KB (8 pages)
06/12/2024 10:04 am Section 708A Cleansing Statement 218KB (2 pages)
14/11/2024 8:36 am 2024 AGM Presentation 3411KB (14 pages)
14/11/2024 8:33 am AGM Chair Address 333KB (3 pages)
29/10/2024 9:26 am Quarterly Activities/Appendix 4C Cash Flow Report 525KB (13 pages)
16/10/2024 9:45 am Lumos and BARDA Partnership - Investor Briefing Recording 171KB (2 pages)
14/10/2024 12:28 pm Cancel - Proposed issue of securities - LDX 16KB (5 pages)
14/10/2024 11:18 am Proposed issue of securities - LDX 15KB (5 pages)
14/10/2024 10:53 am Notice of Annual General Meeting and Proxy Form 616KB (30 pages)
11/10/2024 3:14 pm Change in substantial holding 114KB (2 pages)
11/10/2024 9:21 am Lumos and BARDA Partnership - Investor Presentation 651KB (9 pages)
10/10/2024 9:11 am Change of Director's Interest Notice - SL 270KB (3 pages)
10/10/2024 9:06 am Change of Director's Interest Notice - CR 218KB (2 pages)
10/10/2024 9:03 am Change of Director's Interest Notice - BLG 219KB (3 pages)
09/10/2024 4:29 pm Change in substantial holding from RYD 146KB (3 pages)
09/10/2024 3:31 pm Lumos and BARDA Partnership - Investor Briefing 208KB (2 pages)
09/10/2024 11:45 am Notification regarding unquoted securities - LDX 19KB (8 pages)
09/10/2024 11:39 am Application for quotation of securities - LDX 17KB (8 pages)
08/10/2024 8:52 am Lumos Successfully Completes Retail Entitlement Offer 202KB (3 pages)
03/10/2024 9:33 am Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study 310.2KB (3 pages)
25/09/2024 12:23 pm Lumos Awarded National Contract with MediGroup for FebriDx 284.5KB (2 pages)
23/09/2024 4:18 pm Ceasing to be a substantial holder 65.7KB (1 pages)
23/09/2024 2:35 pm Change in substantial holding from RYD 177.0KB (3 pages)
23/09/2024 9:43 am Investor Roadshow Presentation 14.9MB (55 pages)
20/09/2024 10:11 am Lumos Achieves First Phase 2 Milestone in Hologic Agreement 245.8KB (3 pages)
19/09/2024 4:43 pm Change in substantial holding 161.3KB (2 pages)
16/09/2024 2:12 pm Change in substantial holder 193.7KB (2 pages)
16/09/2024 10:54 am Change in substantial holding 175.1KB (2 pages)
16/09/2024 9:28 am Lumos Appoints Thermo Fisher Scientific as US Distributor 189.2KB (2 pages)
13/09/2024 3:52 pm Change in substantial holding from RYD 181.3KB (3 pages)
12/09/2024 10:50 am Application for quotation of securities - LDX 20.7KB (8 pages)
11/09/2024 9:02 am Letter to Ineligible Shareholders 134.5KB (3 pages)
11/09/2024 9:02 am Letter to Eligible Shareholders 19.2MB (98 pages)
11/09/2024 9:01 am Retail Entitlement Offer Booklet 18.9MB (94 pages)
11/09/2024 9:01 am Retail Entitlement Offer Opens 237.7KB (2 pages)
06/09/2024 8:54 am Lumos Successfully Completes Institutional Entitlement Offer 261.3KB (3 pages)
04/09/2024 2:39 pm Becoming a substantial holder 210.3KB (2 pages)
04/09/2024 12:00 pm Ceasing to be a substantial holder 125.6KB (2 pages)
04/09/2024 10:53 am Proposed issue of securities - LDX 18.5KB (5 pages)
04/09/2024 10:52 am Proposed issue of securities - LDX 24.8KB (7 pages)
04/09/2024 10:38 am Entitlement Offer Cleansing Notice 232.0KB (3 pages)
04/09/2024 10:38 am Investor Presentation 18.1MB (53 pages)
04/09/2024 10:38 am Lumos Announces $10m Equity Raising and Welcomes Tenmile 332.8KB (6 pages)
04/09/2024 9:27 am Trading Halt 631.9KB (2 pages)
03/09/2024 4:35 pm Lumos Announces Intention to Undertake Entitlement Offer 334.9KB (3 pages)
27/08/2024 9:39 am Appendix 4G and Corporate Governance Statement 808.1KB (27 pages)
27/08/2024 9:36 am FY24 Full Year Results Announcement 287.8KB (5 pages)
27/08/2024 9:29 am FY24 Annual Report 3.4MB (77 pages)
27/08/2024 9:22 am FY24 Appendix 4E 201.7KB (2 pages)
26/08/2024 8:39 am Lumos and BDI Progress New Point of Care Test 329.7KB (3 pages)
05/08/2024 10:21 am Lumos Receives Research & Development Tax Rebate 286.5KB (2 pages)
01/08/2024 10:13 am Q4 FY24 Investor Presentation 1.3MB (20 pages)
31/07/2024 8:59 am Quarterly Activities/Appendix 4C Cash Flow Report 612.1KB (12 pages)
29/07/2024 2:32 pm Q4 FY24 Results Investor Briefing Invitation 282.4KB (2 pages)
11/07/2024 8:58 am Notification of cessation of securities - LDX 19.3KB (6 pages)
09/07/2024 8:36 am Lumos Expands Henry Schein FebriDx Distribution Partnership 273.1KB (3 pages)
04/07/2024 8:34 am Lumos Expands Distribution for FebriDx in AUS and NZ 425.6KB (3 pages)
19/06/2024 9:52 am Lumos Receives US$400k Phase 1 Milestone from Hologic 283.0KB (2 pages)
13/06/2024 9:40 am Change of Director's Interest Notice - CR 311.5KB (2 pages)
13/06/2024 9:39 am Change of Director's Interest Notice - SL 317.7KB (2 pages)
04/06/2024 9:12 am Lumos Receives Second US$5 million Hologic IP Payment 245.3KB (3 pages)
28/05/2024 11:37 am March 2024 Appendix 4C - Correction 564.5KB (7 pages)
06/05/2024 8:41 am Lumos Achieves Key Phase 1 Milestone in Hologic Agreement 309.0KB (3 pages)
02/05/2024 2:23 pm Lumos quarterly update video interview with CEO, Doug Ward 221.5KB (2 pages)
01/05/2024 12:09 pm Notification regarding unquoted securities - LDX 21.3KB (8 pages)
23/04/2024 9:10 am Quarterly Activities/Appendix 4C Cash Flow Report 560.2KB (11 pages)
08/04/2024 9:29 am Lumos announces positive FebriDx paediatric study results 374.9KB (4 pages)
02/04/2024 5:13 pm Change in substantial holding 154.1KB (2 pages)
02/04/2024 3:31 pm Application for quotation of securities - LDX 21.1KB (8 pages)
02/04/2024 3:29 pm Section 708A Cleansing Statement 191.8KB (2 pages)
29/02/2024 5:50 pm Change in substantial holding 229.5KB (2 pages)
28/02/2024 8:54 am Half Year Results Investor Presentation 3.8MB (32 pages)
28/02/2024 8:51 am Appendix 4D and Half Year Report 1.4MB (28 pages)
23/02/2024 11:58 am 1H FY24 Results Investor Briefing Invitation 252.9KB (2 pages)
14/02/2024 4:38 pm Change in substantial holding 177.2KB (2 pages)
12/02/2024 9:12 am Lumos Appoints Henry Schein as US Distributor for FebriDx 284.8KB (2 pages)
05/02/2024 9:55 am Lumos Investor Roadshow Presentation 1.5MB (25 pages)
31/01/2024 9:24 am Investor Information Sessions 286.7KB (2 pages)
31/01/2024 9:21 am Quarterly Activities/Appendix 4C Cash Flow Report 599.4KB (12 pages)
19/01/2024 2:46 pm Proposed issue of securities - LDX 30.2KB (6 pages)
19/01/2024 2:42 pm Notification regarding unquoted securities - LDX 34.1KB (9 pages)
17/01/2024 12:00 pm Change in substantial holding 166.3KB (2 pages)
16/01/2024 10:35 am New Hologic Agreements Investor Briefing Presentation 524.2KB (8 pages)
16/01/2024 10:34 am Additional Information Regarding Agreements with Hologic 229.5KB (3 pages)
15/01/2024 2:31 pm Notification of cessation of securities - LDX 27.7KB (6 pages)
15/01/2024 2:20 pm Investor Briefing on new Hologic Agreements 258.3KB (2 pages)
11/01/2024 9:43 am Lumos Signs Major Development and IP Agreements with Hologic 236.3KB (3 pages)
07/12/2023 2:05 pm Change in substantial holding 240.8KB (2 pages)
06/12/2023 8:48 am Commercial Operations Update Webinar Presentation 19.9MB (12 pages)
04/12/2023 1:35 pm Commercial Update Webinar US Product Launch Activities 211.9KB (2 pages)
04/12/2023 8:35 am Lumos Diagnostics FY2023 Full Year Results Webinar 211.0KB (2 pages)
14/11/2023 2:13 pm Becoming a substantial holder from RYD 171.6KB (2 pages)
03/11/2023 3:55 pm Change in substantial holding 216.9KB (2 pages)
03/11/2023 11:35 am Section 708A Cleansing Statement 293.6KB (2 pages)

"Lumos represents a compelling investment opportunity. We have secured strategic partnerships with leading healthcare companies. We are expanding our commercial services division across human health, animal health, food testing and molecular testing. We have secured key FDA clearances for our Point-of-care products. Collectively, our Company has firm foundations for considerable revenue growth."

Doug Ward | Lumos CEO and MD

Innovation at the point-of-care

2024 Lumos Diagnostics

Quick links
Engage with us